Caris Life Sciences (CAI) Net Income towards Common Stockholders (2024 - 2026)

Caris Life Sciences' Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at -$510000.0 for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 99.6% year-over-year to -$510000.0 in Q1 2026; TTM through Mar 2026 was -$411.4 million, a 10.85% decrease from a year earlier, with the FY2025 full-year figure at -$538.0 million, down 42.22% from the prior year.
• Net Income towards Common Stockholders slipped to -$510000.0 in Q1 2026 per CAI's latest filing, from $82.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $82.0 million in Q4 2025 and bottomed at -$517.2 million in Q2 2025.
• The 3-year median for Net Income towards Common Stockholders is -$75.9 million (2024), against an average of -$97.8 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 232.3% in 2025; the steepest drop was 476.07% in 2025.
• Year by year, Net Income towards Common Stockholders stood at -$61.9 million in 2024, then surged by 232.3% to $82.0 million in 2025, then tumbled by 100.62% to -$510000.0 in 2026.
• Per Business Quant, the three latest CAI Net Income towards Common Stockholders figures stand at -$510000.0 (Q1 2026), $82.0 million (Q4 2025), and $24.3 million (Q3 2025).